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ABSTRACT
Premature ovarian insufficiency (POI) is one of the vital reasons of anovulatory infertility among women under 40 years old. 
However, because of the unacknowledged causative factor in most cases, it still remains a huge challenge in gynecology. 
Recently, the most promising opportunities in diagnosing are connected with the use of some serum biomarkers, such as 
interleukin-17 (IL-17), Frizzled-5 protein, Soggy-1 protein and other cytokines. Additionally, environmental toxicants such 
as chemicals and heavy metals might be relevant in the near future when investigating the causes of premature ovar-
ian insufficiency. One of the main aims of the therapy is to focus on maintaining fertility among women with POI, since it is 
essential for patients considering their young age. Among the newest approaches listed there are different types of stem 
cells, oocytes donation and in-vitro activation, all of which are recently gaining in importance.
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INTRODUCTION
Premature ovarian insufficiency (POI) is defined as 
cessation of menstruation before the age of 40. Principal 
symptoms include increased levels of follicle stimulating 
hormone (FSH) and primary or secondary amenorrhea/oli-
gomennorhea prior to the age of 40. Thus, the condition 
leads to a hypoestrogenism and decline of residual ovar-
ian follicles [1].
Premature ovarian insufficiency was originally known 
as premature ovarian failure or premature menopause, but 
these terms are considered as stigmatizing and suggesting 
irreversible infertility. In the guidelines of European Society 
of Human Reproduction and Embryology (ESHRE) from 
2015 regarding this issue “premature ovarian insufficiency” 
was proposed [1]. The following paper includes a litera-
ture review of most recent studies published in English in 
Pubmed/MEDLINE database from January 2014 to Decem-
ber 2020 regarding POI. 
EPIDEMIOLOGY
The prevalence of premature ovarian insufficiency in 
adults under 40 years old is estimated at approximately 
1.1% of women [2]. Results of cross-sectional multi-ethnic 
research show that incidence varies depending on ethnicity 
and is higher among women from Africa and Latin America 
[1]. The prevalence of POI in Sweden is 1.9% (90% of cas-
es are non-iatrogenic), whereas in China it is 2.75% [1, 3]. 
The study conducted in Israel states that the incidence rate 
of new POI diagnoses per 100,000 person/year doubled 
(4.5 vs 2.0) during the years 2009–2016, compared with 
2000–2008, which may explain the difference in prevalence 
between past and up-to-date studies [4].
ETIOLOGY
The etiology of premature ovarian insufficiency is abun-
dant. However, the causative factor in most cases of the 
syndrome still remains unknown. Chromosomal and genetic 
defects can cause POI, including chromosome X defects, 
fragile-X syndrome, and autosomal monogenic and oligo-
genic defects. POI may be also associated with autoimmune 
disorders or infections or have an iatrogenic cause, including 
surgery, radiotherapy, or chemotherapy. Environmental im-
pact is included in causative factors of POI as well [5, 6]. Inci-
dence rates of idiopathic POI have increased by 2.6-fold and 
other etiologies by 3.0-fold, while the incidence of genetic 
disorders such as Turner’s syndrome remained constant 
during the years 2009–2016, compared with 2000–2008 [4].
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Genetic causes
Chromosomal abnormalities and defects can be causa-
tion of POI, their frequency is approximately 10–13% [7]. 
Chromosome X aneuploidies including: Turner syndrome 
(45,XX), mosaic forms (45,X/46,XX and 45,X/47,XXX), trisomy 
X (47,XXX), X-deletions, X-autosomal translocations may lead 
to premature ovarian insufficiency. Another rearrangement 
is CGG repeat in the 5’ regulatory region of the FMR1 gene, 
which causes Fragile-X Syndrome [6]. The premutation of 
FMR1 gene should be investigated in women suffering from 
POI, because approximately 20–30% carriers of this expan-
sion will develop fragile X-associated POI [6, 8]. What is 
more, the region from Xq13.3 to Xq27 has been shown to 
be a critical for normal ovarian function [POI1 (Xq23–Xq27)
and POI2 (Xq13–Xq21)], therefore balanced X-autosome 
translocations or harboring point mutations in this region 
have been associated with POI [6].
Due to an expansion of Next Generation Sequencing 
(NGS), allowing to evaluate numerical changes or genetic 
defects, there are found many novel genes causing non-syn-
dromic POI, that are summarized in Table 1. There are mul-
tiple studies on novel genes associated with premature 
ovarian insufficiency, however most of them are performed 
on small sample sizes and restricted to a single ethnic group 
or even single pedigree line. The cytogenetic, cytogenomic 
(array comparative genomic hybridization) and exome se-
quencing approaches have revealed a genetic causation in 
∼20–25% of POI cases [7].
Summing up, chromosomal analysis should be per-
formed in all patients with non-iatrogenic Premature Ovar-
ian Insufficiency, but autosomal genetic testing is not in-
dicated in women with POI, unless there is an evidence 
suggesting a specific mutation [5].
Autoimmune causes
Evidence for an autoimmune etiology is based on the 
presence of lymphocytic oophoritis, association with other 
autoimmune disorders, and autoantibodies to ovarian an-
tigens. Isolated lymphocytic oophoritis in POI is rare, oc-
curring only in three percent of patients. Autoimmune oo-
phoritis is characterized by cellular infiltration of the theca 
cells of growing follicles by macrophages, natural killer cells, 
T-lymphocytes, plasma cells, and B-lymphocytes. The prime 
target of the autoimmune attack is the steroid-producing 
cells, without damaging the primordial and primary follicles.
Approximately 20% of patients with POI have been al-
ready diagnosed with other concomitant autoimmune en-
docrine diseases like autoimmune thyroid disease (Grave’s 
and Hashimoto’s disease), Addison’s disease, hypopara-
thyroidism, hypophysitis, diabetes mellitus type 1 and 
non-endocrine disorders including chronic candidiasis, 
idiopathic thrombocytopenic purpura, vitiligo, alopecia, 
autoimmune hemolytic anemia, pernicious anemia, sys-
temic lupus erythematosus, myasthenia gravis, rheuma-
toid arthritis, Sjögren’s syndrome, primary biliary cirrhosis, 
chronic active hepatitis, celiac disease and Crohn’s disease. 
Up to 40–50% of the patients with POI are positive for at 
least one organ-specific autoantibody [13].
Addison’s disease and autoimmune polyendocrine 
syndrome (APS) type II are known as clinically important 
factors predisposing to ovarian disorders, therefore affect-
ed women should be counseled and screened for POI [5]. 
APS type II consists of primary adrenal insufficiency, diabetes 
mellitus type 1, autoimmune thyroid disease, celiac disease 
and myasthenia gravis [13]. POI of adrenal autoimmune 
origin is the most frequent type observed in 60 to 80% of 
patients with autoimmune cause of ovarian insufficiency. 
Table 1. Selection of the novel genes involved in non-syndromic POI 







































Meiosis and DNA repair [6, 7, 9, 12]
POLR2C,
MRPS22
Metabolism and protein 
synthesis [6]
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Screening for 21-hydroxylase autoantibodies (21OH-Ab) or 
adrenocortical antibodies (ACA) is recommended in women 
with POI of an unknown cause or if an autoimmune disorder 
is suspected [5].
Thyroid autoimmunity is the most prevalent (25–60%) 
associated endocrine autoimmune disorder reported in 
patients with POI when adrenal autoimmunity is absent 
[13]. Although untreated hypothyroidism is not life threat-
ening, it can have severe impact on the fetal neurocognitive 
development in case of pregnancy. Therefore, according to 
ESHRE guidelines, screening for thyroid antibodies (TPO-Ab) 
should be performed in women with POI. In patients with 
a positive TPO-Ab test, thyroid-stimulating hormone (TSH) 
should be measured every year [5].
Iatrogenic causes
Chemotherapy affects the granulosa and theca cells of 
the ovary more than the oocytes. However, the effect of the 
chemotherapy depends on the drug (Tab. 2), dose, and the 
age of the patient [14]. Women under 40 years old develop 
amenorrhea with high serum gonadotropin concentrations 
during chemotherapy, but menstruation and fertility may 
return several months to years after the cessation of the 
chemotherapy [5, 14].
Unlike cytotoxic therapies, oocytes and ovarian stroma 
are remarkably sensitive to radiation therapy. Ovarian dam-
age also depends on the dose and on the patient’s age. 
In some studies on the dose of radiation that would cause 
ovarian insufficiency in 97.5% of patients, the required dose 
at birth was 20.3 Gy, at 10 years old — 18.4 Gy, at 20 years 
old — 16.5 Gy and at 30 years old — 14.3 Gy. All radiation 
treatments to the pelvic area will likely result in irreversible 
ovarian damage [15].
Environmental causes
Some studies and meta-analysis indicate an association 
between POI and environmental toxicants [5, 16]. Environ-
mental causative factors are presented in Figure 1.
DIAGNOSTICS
Clinical features and diagnostic criteria
Diagnostic criteria to establish the diagnosis of the pre-
mature ovarian insufficiency are based on both presence 
of menstrual disturbances and biochemical assessments. 
It applies to women who are less than 40 years old, includ-
ing patients older than 40 years, but with symptoms onset 
before the age of 40.
Therefore, premature ovarian insufficiency should al-
ways be excluded in women before 40 with oligomenor-
rhea/amenorrhea of more than four months duration or 
estrogen-deficiency symptoms. Primarily, levels of folli-
cle-stimulating hormone (FSH) in serum should be evalu-
ated. The latest recommendations of ESHRE and Polish So-
ciety of Reproductive Medicine and Embryology (PTMRiE) 
proclaim that levels of more than 25 IU/L, obtained twice at 
Table 2. Chemotherapeutic drugs divided into groups according to 
their impact on ovarian insufficiency [14]
Permanent 
hypogonadism
nitrogen mustard, L-phenylalanine mustard, 




vinblastine, cytosine arabinoside, cis-platinum, 
carmustine, lomustine, etoposide, imatinib
Small or hardly 
any impact
methotrexate, 5-fluorouracil, 6-mercaptopurine, 
vincristine, mitomycin
*For most agents, only experimental data are currently available [16]
Figure 1. Environmental causative factors divided into groups by the mechanism of the ovarian damage
• phthalates
Inducers of increased follicle recruitment
• bisphenol-A (BPA)
• polychlorinated biphenyls (PCB)
Chemicals that block follicular stimulation
• 2-bromopropane (2-BP), cadmium,
• 7,12-dimethylbenz[a]anthracene (DMBA), 
Toxicants increasing apoptosis/atresia of 
primordial and primary follicles:
• 4-vinylcyclohexene (VCH), triclosan,
• pesticides like methoxychlor (MXC)
Smoking, alcohol, nutrition, and exposure to endocrine disruptors have been also implicated as influencing 
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least four weeks apart, indicate POI [5, 17]. Whereas accord-
ing to previous recommendations the FSH level needed to 
be greater than 40 IU/L. Anti-Mullerian Hormone (AMH) is 
an important indicator of diminished ovarian reserve, how-
ever, it is not used to establish the diagnosis. Nonetheless, 
in the absence of those symptoms, the change in regular 
menstruation in every case should be a reason to do the 
diagnostic work-up [18, 19].
Besides the fact clinicians should enquire about symp-
toms of estrogen deficiency. Additionally, radiotherapy, 
surgical interventions on ovaries and cigarette smoking 
should always raise the doctor’s vigilance. Thus, con-
scientious inquiry into patients’ medical history seems 
to be crucial. Once the diagnosis is established, further 
assessments need to be done to find a potential cause 
of the disease. 
Serum biomarkers
The most promising opportunities are connected with 
the diagnostic use of a serum biomarkers. Jian Liu et al. 
(2020) suggested that there are many proteins which take 
part in pathogenesis of premature ovarian insufficiency and 
may constitute novel biomarkers of this condition [23]. Se-
rum specific POI proteins profile in patients with POI, healthy 
fertile women and menopausal women were compared. 
Interestingly, in each group the array profile of twelve bio-
markers was different (Tab. 3).
The level of cytokines from interleukin 17 (IL-17) signal-
ing family (IL-17F, IL-17R, IL-17C) was lower in the serum of 
POI patients compared to healthy control group. They are 
involved not only in immune response, but they are also 
a crucial part of development of cancers. Elevated level of 
IL-17 in ovarian cancer is connected with better prognosis, 
so decreased level in patients with POI can suggest ovar-
ian disease. Another protein, which is a prognostic factor 
in ovarian cancer is a receptor of Interferon gamma (IFN-γ), 
IFN-γ R1. Its level was also decreased in POI. Overexpres-
sion of a dominant-negative mutant of IFN-γ R1 lead to 
a decline in immunogenicity in animal studies and the same 
mechanism could appear in patient suffering from POI. 
Downregulation of interleukin 29 (Il-29) may be involved 
in autoimmune response [23].
Decreased level of neurturin protein could be connected 
with problems with follicle maturation or ovulation, as it is 
involved in these processes [23].
Furthermore, in POI serum the level of Frizzled-5 protein 
was decreased. Frizzled-5 is a receptor for Wnt5a protein. 
Abedini et al. (2016) [24] emphasized the influence of Wnt5a 
on women’s fertility, because of suppression gonadotropin 
signaling. Furthermore, Liu et al. [20] suggested that Wnt5a 
may inhibit FSH due to interaction with its receptor. A de-
cline in amount of Frizzled-5, a receptor for Wnt5a, increases 
the level of FSH.
There is no evidence that Soggy-1 have a role in fe-
male fertility, but there are studies about its impact on 
testicular development and spermatogenesis, and thus 
also male fertility. Level of the Soggy-1 protein decreased 
in women with POI. The results of clinical trial have shown 
that the level of the Serpin D1 protein, MMP-7 enzyme, 
Intercellular Adhesion Molecule 3 (ICAM-3) was lower in 
the serum of POI patients when compared with healthy 
control group [23, 26].
Table 3. Proteins candidates for serum biomarkers of POI [20, 23–25]
Protein Serum levels in POI patients compared to healthy control group Characteristic




↓ Prognostic factor in ovarian cancer connected 
with better prognosis 
Interferon gamma receptor 1 (IFN-γ R1) ↓ Prognostic factor in ovarian cancer
Interleukin 29 ↓ Involved in autoimmune response 
Neurturin ↓ Follicle maturation and ovulation
Frizzled-5 ↓ Receptor for Wnt5a protein - FSH inhibitor
Soggy-1 ↓ Impacts testicular development and spermatogenesis, but there is poor evidence for role in female fertility 
Heparin Cofactor II (Serpin D1) ↓ Coagulation factor and a cofactor for heparin 
and dermatan sulfate
Matrix-metalloproteinase -7 (MMP-7) ↓ Involved in the breakdown of extracellular matrix during ovulation and menstruation
Intercellular Adhesion Molecule 3 (ICAM3) ↓ Plays role in cell adhesion, phagocytosis and immune response regulation
Afamin ↑ Marker for oxidative stress
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Interestingly, afamin protein was the only one marker, 
which increased in women with POI. Elevated level of afa-
min occur not only in POI but also in oxidative stress [23].
The clinical trials conducted by Liu et al. have identified 
several potential premature ovarian insufficiency biomark-
ers, which can have greater diagnostic value and appli-
cability in clinical practice. Diagnosis of POI based on the 
detection of genetic abbreviation is extremely expensive 
and complicated, so these results of papers are promising 
and give us hope for easier diagnosis. However, Liu et al. [20] 
emphasize that further studies are needed to confirm their 
result, because it was the first study, which suggested this 




The British Menopause Society and Women’s Health 
Concern, ESHRE and the American College of Obstetricians 
and Gynecologists (ACOG) indicate that management of POI 
should include sex steroid replacement (per os or transder-
mal)–hormone replacement therapy (HRT) or a combined 
hormonal contraceptive until the average age of natural 
menopause is reached, unless they are contraindicated. HRT 
and combined oral contraceptives are offered to women 
with POI to decrease risk of breast cancer, cognitive decline, 
dementia and cardiovascular diseases, to prevent osteo-
porosis, urogenital atrophy and to improve the quality of 
a patient’s life. Achieving the physiological level of estradiol 
is the aim of the HRT. Although the frequency of spontane-
ous pregnancy in women with POI is low and ranges from 
5 to 10%, patients should be advised that the HRT is not 
any contraceptive. For patients avoiding pregnancy com-
bined hormonal contraceptives are more favorable instead 
of HRT. Levonorgestrel intrauterine device insertion is rec-
ommended for women who want highly effective contra-
ception concurrently preferring some non-contraceptive 
HRT [21, 22, 27].
17β-estradiol, ethinyl estradiol and conjugated equine 
estrogens can be used in the therapy. However, estradiol is 
preferred to ethinyl estradiol or conjugated equine estro-
gens considering bone health and cardiovascular health in 
women with POI. The delivery of progestogen is required 
unless the uterus is absent. Oral cyclical micronized natural 
progesterone is related to the lowest risk of cardiovascular 
disorders and breast cancer with the endometrial protection 
compared to the synthetic progestogens [21, 23]. Route of 
administration depends on the patient›s preferences, how-
ever if specific risk factors are present, the transdermal route 
is preferred [5]. Continuous estrogen replacement is recom-
mended to avoid hypoestrogenism’s symptoms. However, 
cyclical regimens that stimulate active functioning of the 
endometrium are required for patients desiring pregnancy 
by oocyte donation, despite the slightly higher risk of the 
endometrial hyperplasia and carcinoma [22].
Appropriate management of reduced bone min-
eral density in POI consists of HRT, calcium and/or vita-
min D supplementation for women with inadequate 
vitamin D status and/or calcium intake. Bisphosphonates 
are not the first-line therapy in women with primary ovar-
ian insufficiency [22, 27].
Hypertension, migraine with aura, history of prior ve-
nous thromboembolism (VTE), obesity, Turner’s syndrome, 
BRCA1/BRCA2 mutation (without a history of breast cancer 
after prophylactic bilateral salpingooophorectomy) and 
fibroids are not contraindications to the HRT, however trans-
dermal delivery of estradiol is preferred. Women with the 
VTE or thrombophilic disorders should be referred to a he-
matologist before the HRT prescription.
Hormone replacement therapy is absolutely contrain-
dicated for breast cancer survivors [21, 27]
If there are any contraindications for hormonal treat-
ment, patient should be provided with management of 
hypoestrogenism’s symptoms, cardiovascular diseases pre-
vention and bone protection [21].
Androgen treatment could be also put into consider-
ation for women with POI, however there are limited studies 
on long-term effects. Androgen replacement therapy is sug-
gested for indications such as memory disorders, neurologi-
cal complaints, diminished sexual functions and decreased 
bone density. Evaluation of the therapy is recommended 
after 2–3 months. Route of administration is similar to the 
treatment with estrogen and progesterone — depending 
on the patient’s preferences [27].
Non-hormonal therapy
Cessation of smoking, moderate alcohol intake, bal-
anced diet, maintaining healthy body weight and regular 
weight-bearing exercises are recommended for the pre-
vention and the therapy of some POI sequelae, especially 
osteoporosis and cardiovascular disorders [27].
Stem cells therapy is considered to be effective in POI 
and infertility due to their self-renewal and regeneration 
potential. There are different types of stem cells used in pre-
mature ovarian insufficiency therapy such as mesenchymal 
stem cells, stem cells from extra-embryonic tissues, induced 
pluripotent stem cells and ovarian stem cells. Many studies 
confirmed that stem cell transplants in mice with POI cause 
a production of ovules and may treat the POI-related infertil-
ity [25]. Another approach to the treatment of POI includes 
the oocytes donation and in vitro activation [29].
Since the diagnosis of POI has a negative impact on 
emotional and psychological wellbeing, the discussion with 
the patient is recommended to identify the need for ap-
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propriate psychological support and counseling or other 
types of therapy provided either on a group or individual 
basis [21, 27].
FERTILITY AND PREGNANCY
One of the principal outcomes of premature ovarian in-
sufficiency are fertility problems. There is a small chance of 
spontaneous pregnancy. Bidet et al. (2011) revealed that 
25% of examined women with idiopathic POI presented 
features, which indicate resumption of ovarian function. 
However, pregnancy occurred in only 4.4% cases [26, 27].
Hitherto the solution recommended is in vitro fertiliza-
tion and embryo transfer (IVF-ET) with the use of donor 
eggs. Frequently, near relatives donate oocytes, though it 
may be donated also from unknown donors. However, in 
group of oocyte donation pregnancies are at high risk of 
obstetric complications e.g., there is a high prevalence 
of miscarriage (40%), in cases of single gestational sac [28].
In vitro activation (IVA) is a novel method, which enables 
patients suffered from POI to activation of their residual dor-
mant follicles. Procedure of IVA consist of ovarian cryopreser-
vation, therapy of PTEN (phosphatase and tensin homolog) 
inhibitor and PI3K (phosphatidylinositol-3-kinase) activator 
and followed auto-transplantation [28].
The procedure begins with ovariectomy of one or both 
ovaries, then medulla of ovary is cut into strips. Histologi-
cal analysis is performed to detect residual follicles. If re-
searcher finds any, the analysis is terminated. Therefore, 
ovarian strips are fragmented into cubes and treated with 
a PTEN enzyme inhibitor or a PI3 K stimulator. Next step is 
the transplantation of ovarian cubes beneath the serosa of 
one or both Fallopian tubes, this procedure is performed 
under laparoscopic surgery. This site was chosen, because 
of high vascularization and convenient monitoring by trans-
vaginal ultrasound and ease for oocyte retrieval for IVF-ET. 
When preovulatory stage is reached by antral follicles IVF 
is done [28, 29].
The results of studies by Kawamura [28] and Suzuki 
[29] consist of 37 women, but histological analysis revealed 
that only 20 of them had residual follicles. Follicle growth 
was noticed in about 50% of patients with residual fol-
licles. In some cases, preovulatory stage are detected after 
six months or longer. IVF and following IVF-ET was done 
in four patients, but pregnancies were detected in three 
patients. The outcomes were one miscarriage and two suc-
cessful deliveries. Endometriosis as a side effect of IVA was 
detected more frequently in patients with residual follicles 
and follicle growth.
Suzuki [29] suggested that histological analyses are 
a better prognosis parameter for predicting in vitro activa-
tion success than serum AMH levels. Their results suggest 
that high level of serum AMH is associated with a better IVA 
outcome. However, some patients with undetectable AMH 
levels responded to in vitro activation treatment.
The results have been promising, but future studies are 
needed to develop a non-invasive method to predict the 
presence of residual follicles and due to that avoid ovari-
ectomy in several cases. Procedure of in vitro activation 
could be also a solution for women suffering from other 
ovarian dysfunction, as well as girls in prepubertal age [28].
Oncofertility is a medical procedure, which aims fertil-
ity preservation in women prepared to cancer treatment 
(radiation or chemotherapy). The choice of appropriate 
method depends on age of patient, diagnosis and type of 
treatment. One of the most popular methods is embryo 
cryopreservation (as a result of in vitro fertilization). This is 
an appreciated form of preserving fertility, which is gaining 
popularity, and best if started within 3 days of the onset of 
cycle. Nevertheless, it is proved that starting the therapy 
in any moment of the cycle should be equally successful. 
There is also a possibility to cryopreservation nonfertilized 
oocytes, recommended in cases, when a patient doesn’t 
have a partner [30, 31].
Ovarian transposition is another method, characterized 
by surgical repositioning during laparotomy or laparoscopy. 
It is especially recommended to patients prepared for radio-
therapy, because ovaries could be moved well beyond the 
planned radiation field [30].
CONCLUSIONS
Premature ovarian insufficiency is a condition of 
wide-ranging etiology that is expanding even more. None-
theless, most causative factors are still not established. Fresh 
approaches of management are deliberated considering not 
only fertility but also patient’s sexuality and novel markers 
related to the development of premature ovarian insuf-
ficiency. The most recent studies suggest that there are 
some cytokines, which may be novel serum biomarkers 
for POI. However, it must be confirmed in other studies. Ex-
pansion of the Next Generation Sequencing contributes to 
increasing the number of novel genes associated with POI 
etiology. In the future sequencing techniques are expected 
to enable discovering new genetic causes of premature 
ovarian insufficiency. However, genetic studies should be 
performed on bigger samples of patients and on different 
ethnic groups. Currently most studies on novel genes apply 
only to specific ethnic groups. Therefore, doctors should be 
aware during counselling patients that some data about ge-
netic causes of POI could be obtained from another ethnic 
group. Fertility problems are of the most serious difficulties 
for women with POI. Several approved methods of fertility 
preservation are available to the patients. However, further 
research on experimental methods (e.g., in vitro activation) 
is in progress.
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